Combination immunotherapy clinical trial for prostate cancer patients with rise in PSA

Prostate cancer imaging

Abnormal Lipid Metabolism in Prostate Cancer
Photo credit: Ji-Xin Cheng

Men with prostate cancer that have experienced biochemically recurrent prostate cancer, a rise in PSA after definitive surgery or radiation, but no evidence of disease on imaging may be eligible for a new clinical trial at the NIH Clinical Center.

Prostate cancer is the second most common cancer in men in the United States and is the second leading cause of death from cancer in men. A study led by Ravi Madan, M.D., Clinical Director of the Genitourinary Malignancies Branch, will test a combination treatment of the immunotherapy drugs PROSTVAC, CV301 and MSB0011359C (M7824) to try and induce an anti-tumor effect. Once a safe dosage is identified in an initial group with metastatic prostate cancer, investigators will study whether the drugs can decrease PSA values for patients with biochemically recurrent prostate cancer.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Sun, 04/01/2018